OS Therapies (OSTX) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OS Therapies (OSTX) has outperformed Tenax Therapeutics (TENX) over the past year, losing 20.6% versus a loss of 76.2%. OS Therapies is the larger company by market cap ($75.8 million vs $69.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSTX | TENX |
|---|---|---|
| Share price | $1.62 | $1.86 |
| Market cap | $75.82M | $69.61M |
| 1-day change | +4.52% | -2.62% |
| YTD return | +15.71% | -84.74% |
| 1-year return | -20.59% | -76.25% |
| 5-year return | — | -99.93% |
| Forward P/E | 4.67 | — |
| EPS (TTM) | $-1.08 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $19.40 |
| 52-week low | $1.15 | $1.31 |
| Distance from 52-week high | -28.00% | -90.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +424.69% | +575.27% |
| Average volume | 586.70K | 5.46M |
| Shares outstanding | 46.81M | 37.42M |
| Employees | 4 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed TENX by 55.7 percentage points over the past year.
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
OSTX vs TENX FAQ
Which is bigger, OS Therapies or Tenax Therapeutics?
OS Therapies (OSTX) is larger, with a market capitalization of $75.82M compared with $69.61M for Tenax Therapeutics (TENX).
Which stock has performed better over the past year, OSTX or TENX?
OSTX returned -20.59% over the past 12 months, compared with -76.25% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are OS Therapies and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.